Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2021 | myDRUG: precision medicine in multiple myeloma

Daniel Auclair • 8 Apr 2021
ESH MM 2021
Multiple Myeloma CAR-T
MyDRUG

Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses precision medicine approaches for the treatment of patients with multiple myeloma. Dr AuClair describes the myDRUG trial (NCT03732703) which is investigating precision medicine approaches in patients with multiple myeloma by using genomic profiling and drugs targeted to affect specific disease-related mutations. Dr AuClair also describes a case study from the myDRUG trial where a mutation in the RAS pathway was identified in patient with myeloma, enabling targeted therapy with promising results. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

More from Daniel Auclair

2:50
IMW 2021: MRD highlights
Daniel Auclair • 11 Sep 2021
5:24
Novel immunotherapies for multiple myeloma
Daniel Auclair • 8 Apr 2021
5:58
What’s to come for the MMRF in 2021?
Daniel Auclair • 15 Dec 2020
2:04
How has COVID-19 affected the myeloma field?
Daniel Auclair • 15 Dec 2020

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals